a 100% natural growth hormone secretagogue © 2006 -2013 millennium health centers, inc. 08-01-2013

Secretropin®

The Millennium Health Centers, Inc.

A 100% Natural

Growth Hormone Secretagogue

A 100% Natural

Growth Hormone Secretagogue

© 2006 -2013 Millennium Health Centers, Inc. 08-01-2013

GORDONMD

1/10/2009

Dr. Mark L. Gordon, M.D.Medical Director, Product Development

Millennium Products

Secretropin®

The Logical “First Step” in GH Therapy.

Secretropin®


© 2006 -2013 Millennium Health Centers, Inc.

GORDONMD

1/10/2009

1. Definition

A secretagogue is a substance that causes another substance to be secreted.

SRxSimulates

GHRF

GrowthHormone


Youthful production of GH and Older Production

The number of pulses and the amplitude of hormone production decreases as we get older.


The Science of SRx

2. The Homeostasis of Growth Hormone

Positive FeedbackGrowth Hormone Releasing Hormone (GHRH)

Negative Feedback

Somatotropin Releasing Inhibiting Factor (SRIF)

aka - Somatostatin


IGF-1IGF-1 GHGH AP

+ -++

SRIFHypothalamus

AP

-

Liver

Low Dose GH Stimulation vs. High Dose Stimulation

Over stimulation of the AP leads to an elevation in the production of Somatostatin with a corresponding decrease in the release of GHRH leading to down regulation in the production of growth hormone.


Somatostatin

The Science of SRx

The Threshold Theory of GH Production

1. GH is a central and peripheral trigger of the feed-back loop.i. Down regulation of GHRH-receptors

ii. Down regulation of Arcuate Nucleus production of GHRH

iii. Up-regulation of Somatostatin (SRIF) from the Paraventricular nucleus of the hypothalamus.

2. IGF-1 is a peripheral trigger of the central feed-back loop.i. Down regulation of GHRH-receptors

ii. Down regulation of Arcuate Nucleus production of GHRH

iii. Up-regulation of Somatostatin (SRIF) from the Paraventricular nucleus of the hypothalamus.


The Science of SRx

The Threshold Theory of GH Production

1. When GH reaches the individual’s threshold for Negative Feedback:

i. Somatostatin increases thereby down-regulating GH production and release.

2. When IGF-1 reaches the individual’s threshold for Negative Feedback:

i. Somatostatin increases thereby down-regulating GHRH and GHRH-r production.


The Science of SRx

Somatostatin 's Impact on GH Production

Preliminary results, from a number of articles, indicate that there is a 40% decrease in intrinsic GH production when injectable GH is used for just 2 days.

Eventually 100% decrease.

Thereafter, the exogenous GH becomes the only source of the hormone.

Recovery can take over a year.

Neuroendocrine Control of Growth Hormone Secretion. PHYSIOLOGICAL REVIEWS Vol. 79, No. 2, April 1999. Eugenio E. Muller, Vittorio Locatelli, Daniela Cocchi, Department of Pharmacology, Chemotherapy, and Toxicology, University of Milan, Milan; and Department of Biomedical and Biotechnology Sciences, University of Brescia, Brescia, Italy


Repeated stimulation of pituitary cell cultures with GH-releasing hormone results in diminished responsiveness, a phenomenon referred to as homologous desensitization.

One component of GHRH-induced desensitization is a reduction in GHRH-binding sites, which is reflected by the decreased ability of GHRH to stimulate a rise in intracellular cAMP.


Homologous Down-Regulation of Growth Hormone-Releasing Hormone Receptor mRNA Levels* Endocrinology

138: 1058–1065, 1997 Grazia Aleppo, Stanley F. MOSKAL II, Paula A. De Grandis, Rhonda D. Kineman,Lawrence A. Frohman, Department of Medicine, Section of Endocrinology and Metabolism, University of Illinois at Chicago, Chicago, Illinois 60612

The

Secretagogue Story

© 2010 Millennium Health Centers, Inc.

Many Secretagogues

GHRFs GHRH

GHGH

GHGH

DHEA

Dopamine

Non-Peptides

Peptides

Arginine

Amino Acids

Vitamin D3

Melatonin


GORDONMD

Slide 7The Hypothylamus monitors the levels of hormones in the blood. Then triggers the spicific increase or decrease of a releasing factor to influence the production level(s) of any hormone.

Novo Nordisk’s Report on Secretagogues

Growth hormone secretagogues: recent advances and applications. DRUG DISCOVERY TODAY 1999 Nov;4(11):497-506 Ankersen Novo Nordisk

A/S, Novo Nordisk Park, DK-2760 Malov, Denmark.

The discovery of a new class of compounds that stimulate the release of growth hormone (GH) in a manner distinctly different from growth hormone-releasing hormone (GHRH) is advancing the understanding of the mechanisms that control GH secretion.

These compounds, the GH secretagogues, act at both pituitary and hypothalamic levels, and even elicit effects in the CNS and peripheral systems.


Growth Hormone-Releasing Peptide (GHRP). Cell

Mol Life Sci. 1998; 54(12):1316-29. Bowers CY. Tulane University Medical School, New Orleans, Louisiana 70112, USA.

Growth Hormone-Releasing Peptides and Non-Peptides are a chemical class of Growth Hormone secretagogues with a chemistry that ranges from small synthetic peptides to peptidomimetics (natural) substances.

They have no structural homology with (GHRH) but act via specific receptors, which are present at both the pituitary and hypothalamic levels.


The Science of SRx

Specific receptors for synthetic GH Secretagogues in the human brain and pituitary gland. Journal of Endocrinology (1998) 157, 99–106. G Muccioli, Et Al. Department of Anatomy, Pharmacology and Forensic Medicine, Department of Biomedical Sciences and Human Oncology, Department of Internal Medicine, University of Turin, Turin, Italy, Pharmacia and Upjohn, Stockholm, Sweden, Europeptides, Argenteuil, France, and Faculty of Pharmacy, University of Montreal, Montreal, Canada.

A number of research centers have identified specific receptors in the human brain and pituitary gland that are unique for sGHS.

These compounds are believed to be the synthetic counterpart of an endogenous GH secretagogue involved in the neuroendocrine control of GH secretion ( Ghrelin).


The Science of SRx

Endocrine and non-endocrine activities of growth hormone secretagogues in humans. Hormone Research. 1999;

51 Suppl 3:9-15. Ghigo E; Arvat E; Broglio F; Giordano R; Gianotti L; Muccioli G; Papotti M; Graziani A; Bisi G; Deghenghi R; Camanni F Department of Internal Medicine, University of Turin, Italy.

Furthermore, these secretagogues (s-GHS) have been found to possess strong, dose-dependent and reproducible GH releasing effects.


The Science of SRx

DHEA in vitro, directly or indirectly through conversion into metabolites, is able to modulate the hormonal response of the pituitary to hypothalamic regulators.

DHEA enhances pituitary prolactin release and induces GH secretion.

These effects could help explain some of the beneficial side effects observed in patients on prolonged DHEA treatments, and therefore, should be taken into account when considering its use.

Dehydroepiandrosterone modulates GHRH, Somatostatin, and angiotensin II action at the pituitary level . Journal of Endocrinology (2005) 185,

165–172C Suárez, J Vela, I García-Tornadú and D Becu-Villalobos Instituto de Biología y Medicina Experimental, CONICET, V, Obligado 2490, Buenos Aires 1428, Argentina.


DHEA replacement in female patients lead to a 20% reduction in the dose of GH for a constant serum IGF-I.

This was maintained for 12 months and there was a significant fall in serum IGF-I two months after withdrawal of DHEA.

Therefore, take at night and not in the morning to enhance GH production.

Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement. Clin Endocrinol (Oxf). 2006; 65(5):673-80,Brooke AM; Centre for Clinical Endocrinology, William Harvey Research Institute, St.Bartholomew's Hospital, QMUL, London, UK.


The Dopamine receptor (DRD2) plays a major role in growth hormone (GH) secretion.

Binding to D2R increases the production and release of Growth Hormone.

Allelic variations of the D2 dopamine receptor gene in children with idiopathic short stature. J Hum Genet. 1999;44(1):26-9. Miyake H,

Nagashima K, Onigata K, Nagashima T, Takano Y, Morikawa A.Department of Pediatrics, Gunma University School of Medicine, Japan.


The effect of L-dopa, on GH secretion was studied in a group of patients with Parkinson's disease undergoing treatment with the drug.

The rise in plasma GH persisted for 120 minutes after the administration of the drug.

( The L-dopa-induced rise in plasma GH could not be blocked by either oral or intravenous glucose administration. )

Stimulation of Human-Growth-Hormone Secretion by L-Dopa .

N Engl J Med 1970; 283:1425-1429 Dec. 24, 1970. A. E. Boyd, III, M.D., Harold E. Lebovitz, M.D., and John B. Pfeiffer, M.D. From the divisions of Endocrinology and Neurology, Department of Medicine, Duke University Medical Center.


Use of amino acids as growth hormone-releasing agents by athletes. Nutrition. 2002 Jul-Aug;18(7-8):657-61. Chromiak JA, Antonio J.Department of Health, Physical Education, Recreation and Sport, Mississippi State University, PO Box 6186, Mississippi State, MS 39762-6186, USA.

Specific amino acids, such as arginine, lysine and ornithine, have been shown to stimulate GH release when infused intravenously or administered orally.Although parenteral administration consistently leads to increased circulating GH concentration, oral doses that are great enough to induce significant GH release are also likely to cause GI discomfort and diarrhea.


The Science of SRx

Product(s) Response

Arginine 250mg/kg/day 60% increase in GH

Ornithine 400% increase in baseline

IV Ornithine 500% increase of GH over baseline.

Alpha-KetoGlutarate

Significant increase in GH in TBI patients.

Glutamine 2 grams increase GH

GABA 5 grams increase GH

Glycine 6.7grams increased GH 300-400%

Amino Acid Secretagogues


Arginine stimulates growth hormone secretion by suppressing endogenous Somatostatin secretion. Journal of Clinical Endocrinology & Metabolism, Vol 67, 1186-1189, 1988. J Alba-Roth, OA Muller, J Schopohl, K von Werder Medizinische Klinik Innenstadt, University of Munich, West Germany.

Arginine administered with GHRH led to higher serum GH levels than did a maximally stimulatory dose of GHRH or Arginine alone.

This indicated that the stimulatory effects of Arginine are mediated by suppression of endogenous Somatostatin secretion (SRIF).


The Science of SRx

Vitamin D and growth hormone regulate growth hormone/insulin-like growth factor (GH–IGF) axis gene expression in human fetal epiphyseal chondrocytes. Growth Hormone & IGF Research Volume 19, Issue 3, June 2009, Pages 232–237. M. Fernández-Cancio,

Vitamin D, dose-dependently, stimulated GHR, IGF-I , and IGFBP-3 expression.

24© 2006 -2013 Millennium Health Centers, Inc.

Peripheral estrogen receptor alpha selectively modulates the waveform of GH secretory bursts in healthy women. Veldhuis JD, Keenan DM, Bowers CY. Am J Physiol Regul Integr Comp Physiol. 2007 Oct;293(4):R1514-21. Epub 2007 Aug . Endocrine Research Unit, Mayo Medical and Graduate Schools, Clinical Translational Research Unit, Mayo Clinic, Rochester, MN55905, USA.

Estradiol drives GH secretion via estrogen receptors (ER-α) located in the hypothalamus and pituitary gland.


Supraphysiological testosterone concentrations increase GH and IGF-I production in the elderly male without altering maximal somatotrope responses to single and combined GHRH and GHRP-2 drive, thus predicting multifactorial mechanisms of testosterone up-regulation.

Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy. Eur J Endocrinol. 2005; 153(4):577-86 Veldhuis JD; et. Al, . Dept of Internal Medicine, Mayo Medical and Graduate Schools of Medicine, General Clinical Research Center, Mayo Clinic, Rochester, MN 55905, USA.


Other GH InfluencersItem Increase Decrease

Melatonin +Estradiol +Dopamine +DHEA +Testosterone +Tamoxifen --Sermorelin +Vitamin D +Alcohol --FATS -Carbohydrates -Obesity --


Summary - The research literature supports the ability of atypical substances to increase the production and release of Growth Hormone through a number of receptor pathways. - These substances have been found to be amino acids, non-peptides, peptides, synthetic peptides, DHEA, Dopamine, which enhance the activity level of Somatotropes increasing production of GH.

- To work they must be introduced into a homeostatic hormonal environment.


The Science of SRx

Nano-Liposomal Delivery


TBImedlegal.com

Nanoliposomal Encapsulation

Dopamine

DHEA

Arginine

Amino AcidsMelatonin

Peptides

Vitamin D

HCl

HCl

HCl


Protection from AcidDestruction.

Nano-Liposomes filled with SRx


The Science of SRx

Nano-spheres or emulsionsto diffuse into the blood.

Size does matter!

Liposomal delivery systems are effective vehicles to incorporate active agents into compartmentalized structures for the delivery of pharmaceutical, cosmetic, food and nutritional products.

A major benefit of liposomal delivery systems is that they allow for spatial and temporal distribution of a drug in the body, reducing unwanted toxic side effects and increasing efficiency of treatment.


Analytical methods for the control of liposomal delivery systems. Revue TrAC. Trends in analytical chemistry, 2006, vol. 25, pp. 167-178. Gomez-Hen. ; Fernandez-

Romero J. M.

Oral vs Liposomal

Product to Deliver Delivery Absorption

Vitamin C (1000mg) Oral 19%

Vitamin C (1000mg) Liposomal 97%


1 gram of orally ingested Vitamin C had a 19% absorption while 1 gram in a Nanoliposomal based product had a 97% delivery.

The original clinical testing of Secretropin was performed in 2001. The original formula delivered by nanoliposomes was found to increase the production of GH based upon a measurable increase in IGF-1.

At that time, IGF-1 was the only test used to monitor responsiveness to the product. Today IGFBP-3 has been shown to be logarithmically proportional to GH production.


2001 – The Initial Testing

The October 2006 Study SequenceThe March 2008 Report. The March 2009 Report and pending March 2013.

Goal to have 100 patients followed for 6

– 12 months with labs drawn initially and

monthly thereafter.


2006 Follow-up Study

257.93

129.77

231.83211.49

0

50

100

150

200

250

300

Initial 1 month 3 months 6 months

62.9% 78.6% 98.7%


The Science of SRx

MK. 50 y/o Female 233%

Stopped SRx due to increased muscularity. Levels dropped.

Result 6/21/2007 3/22/2007 1/09/2007

IGF-1 125.4 230.8 213 99.1

IGFBP-3 3652 5262 5147 4135


The Science of SRx

JC, 47 y/o Male. 238% Increase

TBI case, 5 TBI, 3 LOC, one hospitalization.

Result Range 9/06/2007 4/04/2007 12/26/2006

IGF-1 246.9 > 200 ng/ml 276.2 290 122

IGFBP-3 5693 > 4000 ng/ml 6527 6527 5450


The Science of SRx

NJ: 34 y/o Male 199.2%

Cryptorchism.

Result Range 1/10/2008 10/30/2007 2/20/2007

IGF-1 306.9 > 200 ng/ml 290.8 240 154

IGFBP-3 3824 > 4000 ng/ml 3767 3882 2830

The Science of SRx


Clinical Results

0

50

100

150

200

250

300

350

Patient 1Patient 2Patient 3Patient 4*Patient 5Patient 6

Generally speaking: High initial IGF-1/BP-3 are more prone to shut down then those with initial low IGF-1/BP-3 levels.

Continuous4 - sprays


21

3

4

IGF-1 Results at approx. 1 month intervals (3mos)

6

5

Growth Hormone Algorithm

Initial Treatment

Secretropin (SRx)

1mo Laboratory

No Change/DecreaseIncrease

Continue Adjust Dosing3mos

FailedGlucagonChallenge

Testing

3mos


Secretropin GH Protocol

Program Secretropin Growth Hormone

Initial Protocol 4 sprays to start None

Combined protocol 4 sprays, adjust 0.1mg – 0.3mg

Established GH Use 4 sprays to start. Reduce GH based upon response.

Post-GH Shutdown 4 Sprays, adjust. None

1. In a GH deficient or insufficient patient start SRx and adjust dose for maximal response. Monitor over 3 months.

2. Starting a new patient on both GH and SRx allows for the use of a lower dose of GH with comparable results in both IGF-1 and BP-3 levels.

3. In a patient already on GH, add SRx and adjust for maximal IGF-1/BP-3 levels. You should have a spike in GH production within 3 months.

4. Patients who have been on GH for 6 months or more should start SRx having both IGF-1 and GH monitored. Before starting SRx, wait 4 weeks before taking initial IGF-1 and BP-3 levels for baseline. Monitor Q3months.


Secretropin®



2013 data shows a 20% to a 650% increase in IGF-1 and BP-3 levels in over 89% of the patients.

Over 11 years of Clinical Trials showing the efficacy based upon rising blood levels of IGF-1/BP-3.

A Physician ONLY product. Logically, Secretropin before GH. Logically, cost considerations. Logically, avoid the requirements

of legally prescribing GH.

GORDONMD

1/10/2009

a 100% natural growth hormone secretagogue © 2006 -2013 millennium health centers, inc. 08-01-2013

Documents

hormone ghrh

millennium health centers

production of growth

somatostatin slide

release of growth hormone

regulation of ghrh

youthful production

gh therapy